Shattuck Labs (STTK) EBITDA (2019 - 2026)
Shattuck Labs (STTK) reported EBITDA of -$14.8 million for Q1 2026, down 7.8% year-over-year from -$16.0 million in Q1 2025, and down 17.34% on a QoQ basis from -$12.6 million in Q4 2025.
Shattuck Labs (STTK) has 8 years of EBITDA data on file, last reported at -$14.8 million in Q1 2026.
- Quarterly EBITDA fell 7.8% year-over-year to -$14.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.9 million (up 29.35% YoY) and the FY2025 annual result came in at -$48.8 million, up 35.28% from the prior year.
- EBITDA fell to -$14.8 million in Q1 2026 per STTK's latest filing, from -$12.6 million in the prior quarter.
- Across five years, EBITDA topped out at -$10.1 million in Q3 2025 and bottomed at -$28.0 million in Q2 2022.
- The 5-year median for EBITDA is -$18.7 million (2024), against an average of -$19.3 million.
- The widest annual swing landed in 2022, when EBITDA sank 373.8%; it then jumped 42.18% in 2025.
- Tracing STTK's EBITDA over 5 years: stood at -$25.0 million in 2022, then advanced by 29.11% to -$17.7 million in 2023, then dropped by 5.87% to -$18.7 million in 2024, then jumped by 32.78% to -$12.6 million in 2025, then fell by 17.34% to -$14.8 million in 2026.
- Per Business Quant, the three latest STTK EBITDA figures stand at -$14.8 million (Q1 2026), -$12.6 million (Q4 2025), and -$10.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Shattuck Labs | 667.80 Mn | 667.80 Mn | - | -14.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.77 Mn |
| Dec 31, 2025 | -12.59 Mn |
| Sep 30, 2025 | -10.05 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Mar 31, 2025 | -13.70 Mn |
| Dec 31, 2024 | -18.73 Mn |
| Sep 30, 2024 | -16.62 Mn |
| Jun 30, 2024 | -21.54 Mn |
| Mar 31, 2024 | -18.52 Mn |
| Dec 31, 2023 | -17.69 Mn |
| Sep 30, 2023 | -27.46 Mn |
| Jun 30, 2023 | -21.08 Mn |
| Mar 31, 2023 | -20.19 Mn |
| Dec 31, 2022 | -24.95 Mn |
| Sep 30, 2022 | -24.86 Mn |
| Jun 30, 2022 | -27.95 Mn |
| Mar 31, 2022 | -24.50 Mn |
| Dec 31, 2021 | 9.11 Mn |
| Sep 30, 2021 | -17.62 Mn |
| Jun 30, 2021 | -24.56 Mn |
| Mar 31, 2021 | -12.41 Mn |
| Dec 31, 2020 | -12.07 Mn |
| Sep 30, 2020 | -11.86 Mn |
| Jun 30, 2020 | -6.31 Mn |
| Mar 31, 2020 | -6.49 Mn |
| Dec 31, 2019 | -7.43 Mn |
| Sep 30, 2019 | -7.27 Mn |